$ETSY

Silverman Josh sold $6.9M of ETSY

Silverman Josh sold 92,404 shares of ETSY INC (ETSY) at an average of $74.93 ($74.05–$75.95, $6.92M total) across 3 trades on 2026-07-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Silverman Josh
Published Jul 6, 2026, 9:50 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 6, 2026, 9:53 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ETSY
Neutral
medium confidence
Mentioned
$ETSY
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ETSYNeutralLow
01

Why it matters

The newest concrete fact is the disclosed sale size, price range ($74.05–$75.95), and that it was executed under a pre-arranged 10b5-1 plan.

02

Market read

Traders may briefly reassess positioning around insider activity, but the 10b5-1 nature makes it less actionable than earnings, guidance, or enforcement news.

03

What to watch

The filing doesn’t state reasons for the sale or any concurrent insider buys; without follow-on transactions, it’s hard to infer directionality.

Relevance 5/10Novelty 3/10Timing: Filed July 6 for a July 1 insider sale execution.

Background

The article is an SEC Form 4 insider transaction disclosure for ETSY, filed July 6, covering sales executed July 1.

Company-level read

Ticker impact

$ETSYNeutralMedium confidence
Context

SEC Form 4 shows director Josh Silverman sold 92,404 shares of ETSY for about $6.92M under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any effect would be sentiment-only and typically fades.

Evidence & confidence

The filing is a pre-arranged 10b5-1 open-market sale by a director, with no accompanying company-specific operational or financial change disclosed.

Market effects

Minimal; this is company-specific insider transaction data with no sector-wide read-across.

None indicated.

None indicated.

Counterpoint

Because it’s a 10b5-1 plan, the sale may not reflect bearish expectations; traders may discount it more than typical insider-selling headlines.

Key entities

  • ETSY

    Issuer of the Form 4 insider transaction; director Josh Silverman sold 92,404 shares.

  • Josh Silverman

    Director who executed the open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$WMTMed

Retailers Report AI-Driven Sales, Bigger Baskets in Q2 Earnings

Walmart, Amazon, and Target reported Q2 earnings showing AI-driven sales growth. Walmart's eCommerce grew 23%, with AI assistant users spending 40% more. Amazon's Alexa for Shopping saw active users nearly double. Target's digital traffic from AI platforms grew over 3.5x faster than the industry average. Albertsons saw a 10-26% increase in order value with AI tools. Shopify's AI-referred traffic and orders tripled, but AI's impact on discovery-driven retail remains uncertain.

$ETSYHigh

Bank of America Resets Etsy Stock Price Target After Event

Bank of America upgraded Etsy to Buy, raising its price target to $105 from $88, citing structural growth. The bank expects mid-single-digit gross merchandise sales growth, higher profitability, and increased shareholder returns. Etsy's new management team is seen as key to reinvigorating growth. BofA raised its fiscal 2027 estimates for gross merchandise sales, EBITDA, and EPS.

$DEMed

Premarket movers: Deere jumps following upbeat Q3, Wolfspeed plunges

Deere shares rose 5.1% after reporting stronger-than-expected Q3 results, with EPS of $5.10 and net sales of $11B. CrowdStrike fell 2.8% following its CTO's departure. Advance Auto Parts dropped 15.9% due to lower normalized earnings. Etsy gained 3.9% after a BofA upgrade. Ultragenyx surged 11.1% on FDA approval for a gene therapy. Moderna fell 13% after a prior surge. Wolfspeed plunged 10.5% on wider-than-expected Q4 loss. Webull rose 13.8% on strong Q2 results.